Zelira Therapeutics Ltd has released a press release.
Zeldas Phase II Insomnia Clinical Trial Fully Enrolled
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- September 2019 Quarterly Report
- Zelda to merge with US-based Ilera Therapeutics
- Zeldas Autism Observational Study Recruits 100th Participant
- June 2019 Quarterly Report
- Zelda Collaborates with Emerald Clinics
Later from Zelira Therapeutics
- Formulations to be supplied as part of CARE NSW trial
- Agreement with Health House to Distribute Zelda Products
- Ilera Therapeutics Merger Completed and Board Changes
- Zelira Therapeutics expands HOPE distribution in the U.S.A
- Zelira to Collaborate with the Parkinsons Foundation
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics